dc.relation.reference | 張天鈞,甲狀腺髓質癌診治新進展,當代醫學,第27卷,民國89年:90-2.
張天鈞,細針吸引細胞學比較難以診斷的甲狀腺髓質,當代醫學,第28卷,民國90年:448-52.
張天鈞,基因時代的甲狀腺髓質癌處理原則,當代醫學,第31卷,民國93年:809-11.
鄭添貴,李建賢,王惠暢,邱仁輝,雷永耀,甲狀腺髓質癌之持續性抑鈣激素升高及DNA含量分析之研究,Clin Med J(Taipei)1993;51:340-4.
Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes
in human diseases. J Cell Physiol 2003;195:168-86.
Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cyto & Grow Factor Rev 2005;16:441-67.
Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, et al. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 2005;90:6232-6.
Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol 2005;17:7-12.
Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med 2004;257:1-11.
Carlomagno F, Santoro M. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J Chemotherapy 2004;16 suppl 4:49-51.
Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-90.
Carlomagno F, Santoro M. Receptor tyrosine kinases as targets for anticancer therapeutics. Curr Med Chemistry 2005;12:1773-81.
Carney JA. Familial Multiple Endocrine Neoplasia-The First 100 Years. Am J Surg Pathol 2005;29:254-74.
Chang TJ, Wu SL, Chang TC, Huang SH, Chang TJ. De Novo RET Proto-oncogene Mutation in a Patient with Multiple Endocrine Neoplasia Type 2B. J Formos Med Assoc 1999;98:692-7.
Chang TC, Wu SL, Hsiao YL. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations. Acta Cytologica 2005;49:477-82.
Chen MH, Chang CC, Huang TS, Tsai KS, Chen MH, Huang SH, et al. Factors affecting long-term survival of Taiwanese patients with medullary thyroid carcinoma. J Formos Med Assoc 2003;102:73-8.
Cohen M.S, Moley J.F. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003; 253:616-26.
Cote GJ, Gagel RF. Lessons Learned from the Management of a Rare Genetic Cancer. N Engl J Med 2003;349:1566-8.
Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN 2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 2004;96:1006-14.
Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB, Cerutti JM. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 2004;88:5438-43.
Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 1998;7:129-34.
Drosten M, Stiewe T, Pützer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 2003;14:971-82.
Drosten M, Pützer BM. Gene therapeutic approaches for medullary carcinoma treatment. J Mol Med 2003;81:411-9.
Dvorakova S, Vaclavikova E, Duskova J, Vlcek P, Ryska A, Bendlova B. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J Endocrinol Invest 2005;28:905-9.
Elisei R, Bottici V, Luchetti F, Coscio GD, Romei C, Grasso L, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004;89:163-8.
Erdogan MF, Gursoy A, Ozgen G, Cakir M. Bayram F, Ersoy R, et al. Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study. J Endocrinol Invest 2005;28:806-9.
Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D, Schackert HK. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene code 790/791 germline mutations. Ann Surg 2002;236:570-5.
Gonzalez B, Salcedo M, Medrano ME, Mantilla A, Quinonez G, Benitez-Bribiesca L, et al. RET oncogene mutations in medullary thyroid carcinoma in Mexican families. Arch Med Res 2003;34:41-9.
Gonzalez-Yebra B, Medrano ME, Mantilla A, Mantilla A, Palma V, Colin C, et al. Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation. Endocr Pathol 2003;14:71-80.
Gil L, Azanedo M, Pollan M, Cristobal E, Arribas B, Garcia-Albert L, et al. Genetic analysis of RET, GFR alpha 1 and GDNF genes in Spanish families with multiple endocrine neoplasia type 2A. Int J Cancer 2002;99:299-304.
Gimm O, Sutter T, Dralle H. Diagnosis and therapy of sporadic and familial medullary thyroid
carcinoma. J Cancer Res Clin Oncol 2001;127:156-65.
Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000;37:817-827.
Heerden JA, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990;212:394-400.
Ho C, Lin JD, Huang YY, Huang HS, Huang BY, Hsueh C. Clinical experience of medullary thyroid carcinoma in Chang Gung memorial hospital. Chang Gung Med J 1996;19:142-8.
Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6.
Huang CN, Wu SL, Chang TC, Huang SH, Chang TJ. RET Protooncogene Mutations in Patients with Apparently Sporadic Medullary Thyroid Carcinoma. J Formos Med Assoc 1998;97:541-6.
Huang SH, Kou MS, Jin YT, Liu HT, Wang WP. Prophylactic total thyroidectomy in an 8-year-old girl with multiple endocrine neoplasia type 2A. J Formos Med Assoc 2001;100:274-6.
Huang SH, Lee CH, Chou FF, Liaw KY, Wu TC, and Taiwan Endocrine Surgeons Study Group. Characteristics of thyroidectomy in Taiwan. J Formos Med Assoc 2005;104:6-11.
Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004;204:197-211.
Jain S, Watson MA, DeBenedetti MK, Hiraki Y, Moley JF, Milbrandt J. Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res 2004;64:3907-13.
Jemal A, Tiwari RC, Murry T, Ghafoor A, et al. American Cancer Society 2004 Cancer Statistics. CA Cancer J Clin 2004;54:8-29.
Jindrichova S, Kodet R, Krskova L, Vlcek P. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J Mol Med 2003;81:819-23.
Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Science 2005;96:143-8.
Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, and Heitz PU.
RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1996;81:2041-6.
Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005;15:531-44.
Kruckeberg KE, Thibodeau SN. Pyrosequencing Technology as a Method for the Diagnosis of Multiple Endocrine Neoplasia Type 2. Clin Chem 2004;50:522-9.
Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol 2004;61:299-310.
Lee DC, Chan KW, Chan SY. RET receptor tyrosine kinase isoforms in kidney function and disease. Oncogene 2002;21:5582-92.
Lesueur F, Cebrian A, Robledo M, Niccoli-Sire P, Svensson KA, Pinson S, et al. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res 2006;66:1177-80.
Lindahl M, Poteryaev D, Yu L, Arumäe U, Timmusk T, Bongarzone I, et al. Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. J Biol Chem 2001;276:9344-51.
Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-35.
Lips CJ, Hoppener JW, van Nesselrooij BP, van der Luijt RB. Counselling in multiple endocrine neoplasia syndromes: from individual experience to general guidelines. J Intern Med 2005;257:69-77.
Machens A, Niccoli-Sire P, Högel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, et al. for the European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-25.
Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005;257:50-9.
Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2005;90:3999-4003.
Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, et al. The identification of false positive responses to the pentegastrin stimulation test in RET mutation negative members of MEN2A families. Clin Endocrinol 1996;44:213-20.
Massoll N, Mazzaferri EL, MACP. Diagnosis and management of medullary thyroid carcinoma. Clin Lab Med 2004;24:49-83.
Marx SJ, Stratakis CA. Multiple endocrine neoplasia-introduction. J Intern Med 2005;257:2-5.
Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 1999;90:1-5.
Moore FD, Dluhy RG. Prophylactic thyroidectomy in MEN-2A- a stitch in time? N Engl J Med 2005;353:1162-4.
Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, et al. International RET Mutation Consortium. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995;238:343-6.
Panta GR, Du L, Nwariaku FE, Kim LT. Direct phosphorylation of proliferative and survival pathway proteins by RET. Surgery 2005;138:269-74.
Patocs A, Valkusz Z, Igaz P, Balogh K, Toth M, Verga I, Racz K. Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer. Clin Genet 2003;63:219-23.
Pigny P, Bauters C, Wemeau JL, Houcke ML, Crepin M, Caron P, et al. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 1999;84:1700-4.
Russo A, Zanna I, Tubiolo C, Milgliavacca M, Bazan V, Latteri MA, et al. Herditary common cancers: molecular and clinical genetics. Anticancer Res 2000;20:4841-52.
Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-3.
Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology 2004;145:5448-51.
Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S & Schlumberger M. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88:2070-5.
Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-13.
Sigglekow H, Melzer A, Nolte W, Karsten K, Hoppner W, Hufner M. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy. Eur J Endocrinol 2001;144:467-73.
Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 2006;91:79-84.
Suhuffenecker I, Ginet N, Goldgar D, Eng C, Chambe B, Boneu A, et al. Prevalence and parental origin of de novo RET mutations in MEN 2a and FMTC. Am J Hum Genet 1997;60:233-7.
Takahashi M, Ritz J, Cooper G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42:581-8.
Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988;3:571-8.
Takami H. Medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocr Patholo 2003;14:123-31.
Uchino S, Noguchi S, Sato M, Adachi M, Yamashita H, Watanabe S, et al. Presymptomatic detection and treatment of Japanese carriers of the multiple endocrine neoplasia type 2A gene. Surg Today 1999;29:862-7.
Vanhorne JB, Andrew SD, Harrison KJ, Taylor SA, Thomas B, McDonald TJ, et al. A model for GFRalpha4 function and a potential modifying role in multiple endocrine neoplasia 2. Oncogene 2005;24:1091-7.
van Heurn LW, Schaap C, Sie G, Haagen AAM, Gerver WJ, Freling G, et al. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 1999;34:568-71.
Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-50.
Wu SL, Chang TC, Huang CN, Chuang LM, Chang TJ. Germline RET Proto-oncogene Mutations in Two Taiwanese Families with Multiple Endocrine Neoplasia Type 2A. J Formos Med Assoc 1998;97:614-8.
Yen Tw, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 2003;134:890-9; discussion 899-901.
Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003;138:409-16; discussion 416. | zh_TW |